Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 3/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4189233 | 0.90 | CHRM2 (0.46) | CHRM3CHRM2CHRM1 | |
| SCHEMBL4189353 | 0.89 | CHRM3 (0.46) | CHRM3CHRM2CHRM1 | |
| SCHEMBL4190801 | 0.88 | CHRM3 (0.43) | CHRM3CHRM2CHRM1GRIN2B | |
| SCHEMBL4188612 | 0.88 | CHRM3 (0.43) | CHRM3CHRM2CHRM1GRIN2B | |
| SCHEMBL5105573 | 0.88 | CHRM3 (0.46) | CHRM3CHRM2CHRM1CNR1CNR2 | |
| SCHEMBL5105568 | 0.88 | CHRM3 (0.46) | CHRM3CHRM2CHRM1CNR1CNR2 | |
| SCHEMBL4184610 | 0.85 | CHRM2 (0.61) | CHRM3CHRM2CHRM1 | |
| SCHEMBL4186081 | 0.84 | CHRM3 (0.41) | CHRM3CHRM2CHRM1GRIN2B | |
| SCHEMBL4189224 | 0.83 | GRIN2B (0.48) | GRIN2B | |
| SCHEMBL5511482 | 0.83 | CHRM3 (0.39) | CHRM3CHRM2CHRM1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105221-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-04-23 | — | — | US | disclosed |
| US-20090105221-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105221-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM2 | CHRM3 1/4885CHRM2 3/4885CHRM1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.